Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen.

A significant advancement in weight management has arrived for Singaporeans. Danish pharma Novo Nordisk has announced the ...

Georgia Tech engineers have created a pill that could effectively deliver insulin and other injectable drugs, making ...

Inhaled insulin is effective for controlling blood sugar levels in children with diabetes, providing them with a ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis hasn't changed. Novo Nordisk is still a dominant player in a growing industry, ...

Hims, Ro and LifeMD will soon start selling Wegovy at a reduced price of $499 per month.

The Phase 3 clinical trial found that Wegovy reduced inflammation and scarring in people with metabolic dysfunction-associated steatohepatitis, or MASH.

Engineers use sodium bicarb to “self-pressurize” a pill able to deliver drugs that usually require injection directly to the ...